Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Shares Fell 12.9% in June

By Adria Cimino – Jul 2, 2020 at 3:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A patent ruling involving Biogen’s blockbuster drug weighed on share performance.

What happened

Biogen (BIIB 1.03%) shares slid 12.9% in June, according to data provided by S&P Global Market Intelligence, as the company lost a patent ruling on its blockbuster multiple sclerosis (MS) drug.

In a challenge involving rival Mylan, a federal court in West Virginia invalidated Biogen's Tecfidera patent. The decision clears the way for rival Mylan to bring a generic competitor to market. Biogen plans to appeal, Fierce Pharma reported, citing a statement from the company.

A researcher works in a lab with beakers filled with orange liquid.

Image source: Getty Images.

So what

Biogen's Tecfidera patent would have expired in 2028. That would have offered the company until that time to ramp up sales of its newer MS drug, Vumerity, to compensate for any Tecfidera sales declines. Instead, if Mylan's product comes to market, Biogen faces a more immediate threat to Tecfidera's $4.4 billion in annual revenue.

Mylan's product isn't yet approved, but that may happen soon. Mylan said the U.S. Food and Drug Administration's action date for its drug candidate is Nov. 16 -- but the company is talking with the FDA about possibly advancing that date.

As for Vumerity, launched late last year, sales haven't yet picked up, even though the drug offers the same efficacy as Tecfidera but with fewer side effects. Vumerity brought in $2 million in sales for the first quarter, its first full quarter on the market.

Now what

Pending an appeal, if Mylan's drug is approved, the company may decide to launch it "at risk." An "at risk" launch means selling a generic while patent litigation is ongoing. Meanwhile, according to a Generics Bulletin report, Biogen has obtained a temporary injunction, which could prevent Mylan from making that move.

Whether Mylan is able to launch its drug prior to an appeal decision or not, the West Virginia court decision likely will weigh on Biogen's stock. What may compensate for this and help shares of the biotech company in the coming months is any news on the investigational Alzheimer's disease drug, aducanumab. Biogen plans on completing its submission in the third quarter for FDA review.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$267.00 (1.03%) $2.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.